Antipsychotics are sometimes used in neurodegenerative disease to manage severe psychosis, aggression, or agitation, but they carry substantial risks including sedation, worsening parkinsonism, cerebrovascular events, and increased mortality in older adults with dementia[1][2]. Their role is therefore selective and generally limited to symptoms that create serious distress or safety concerns after non-pharmacological measures have been tried[1:1]. The decision to use antipsychotics in neurodegenerative disease requires careful risk-benefit assessment, informed consent, and ongoing monitoring, as the evidence for efficacy is modest while the risks are substantial[3].
Antipsychotics carry a boxed warning from the U.S. Food and Drug Administration (FDA) regarding increased mortality in elderly patients with dementia-related psychosis. This warning applies to both typical (first-generation) and atypical (second-generation) antipsychotics[4]. Regulatory agencies worldwide have issued similar warnings, and clinical practice guidelines universally recommend that antipsychotics be used at the lowest effective dose for the shortest possible duration in patients with neurodegenerative disease[5].
The FDA approval of brexpiprazole in 2023 for agitation associated with Alzheimer's disease marked the first specifically labeled medication for this indication, though it remains subject to the existing boxed warning for mortality risk in dementia[6].
Antipsychotics exert their effects primarily through blockade of dopamine D2 receptors in the mesolimbic pathway, reducing positive symptoms of psychosis. However, this same mechanism can cause:
Atypical antipsychotics have greater serotonin 5-HT2A receptor blockade relative to D2 blockade, which may reduce EPS risk but does not eliminate movement disorder exacerbation[10].
In Alzheimer's disease, antipsychotics are sometimes prescribed for severe agitation, aggression, or psychosis that threatens patient safety or significantly impairs function. However:
In Parkinson's disease and dementia with Lewy bodies (DLB), antipsychotic use is particularly hazardous because these conditions involve dopamine pathway dysfunction:
Behavioral variant frontotemporal dementia often involves disinhibition, aggression, and compulsive behaviors:
Large cohort studies demonstrate that antipsychotic use in dementia is associated with a 1.5- to 2-fold increase in mortality risk compared to non-use[22]. The risk is highest in the first 4-12 weeks of treatment and with higher doses[23]. This increased mortality appears related to:
Antipsychotics increase stroke risk approximately 1.5- to 3-fold in patients with dementia[28]. The mechanism may involve:
Atypical antipsychotics can cause:
These effects are particularly concerning in populations already at risk for vascular cognitive impairment.
If antipsychotic therapy is initiated, systematic monitoring is essential:
Given the substantial risks, alternatives should be prioritized:
Antipsychotics have a limited role in neurodegenerative disease management due to substantial risks and modest benefits. When used, they should be prescribed at the lowest effective dose for the shortest duration, with regular monitoring and frequent reassessment of ongoing need. Non-pharmacological interventions and alternative pharmacologic approaches should be prioritized.
Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. American Psychiatric Association. 2016. ↩︎ ↩︎
Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Network Open. 2019;2(3):e190916. ↩︎
Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms of dementia in real world settings. American Journal of Geriatric Psychiatry. 2020;28(4):421-436. ↩︎
U.S. Food and Drug Administration. FDA Boxed Warning: Antipsychotics and mortality in dementia. FDA Drug Safety Communication. 2008. ↩︎
National Institute for Health and Care Excellence. Dementia: assessment, management and support. NICE Guidelines. 2018. ↩︎
FDA. FDA approves brexpiprazole for the treatment of agitation associated with Alzheimer's disease. FDA News Release. 2023. ↩︎
Casey DE. Drug-induced extrapyramidal syndromes. Psychiatric Times. 2004;21(13):31-38. ↩︎
Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Expert Opinion on Pharmacotherapy. 2000;1(2):157-168. ↩︎
Petty RG. Prolactin and antipsychotic therapy. Journal of Clinical Psychopharmacology. 1999;19(4):286-294. ↩︎
Meltzer HY, Matsubayashi S, McGurk SR. Comparative effects of clozapine and other antipsychotics on prolactin. Schizophrenia Research. 1995;15(1-2):1-19. ↩︎
Schneider LS, Dagerman K, Insel P. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Psychiatry. 2006;163(2):187-194. ↩︎
Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Annals of Internal Medicine. 2007;146(11):775-786. ↩︎
Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. British Journal of Psychiatry. 2014;205(6):436-442. ↩︎
American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias. American Journal of Psychiatry. 2007;164(12 Suppl):5-56. ↩︎
Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementia. Journal of Neurology, Neurosurgery & Psychiatry. 2005;76(8):1155-1159. ↩︎
McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673-678. ↩︎
FDA. Pimavanserin (Nuplazid) prescribing information. FDA. 2016. ↩︎
Parkinson's Disease Society. The Management of Parkinson's Disease Psychosis. PDS Professional Handbook. 2007. ↩︎
Swanberg MM, Cummings JL. Behavioural disorders in dementia. Current Treatment Options in Neurology. 2002;4(3):185-195. ↩︎
Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer's disease. Journal of Clinical Psychiatry. 1994;55(12):536-538. ↩︎
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477. ↩︎
Wolf A, Leucht S, Pajonk FG. Do antipsychotics increase mortality in dementia? A systematic review and meta-analyses. Innovations in Clinical Neuroscience. 2017;14(7-8):25-30. ↩︎
FDA. FDA Drug Safety Communication: Antipsychotic drug labels. FDA. 2008. ↩︎
Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine. 2009;360(3):225-235. ↩︎
Douglas IJ, Smeeth L. Exposure to antipsychotic drugs and risk of stroke. BMJ. 2008;336(7655):1222-1223. ↩︎
Trifirò G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients. Archives of Internal Medicine. 2010;170(5):411-416. ↩︎
Kolanowski A, Fick DM, Ceroni E, et al. Atypical antipsychotics and falls in older adults. Geriatric Nursing. 2005;26(5):309-312. ↩︎
Douglas IJ, Smeeth L. Exposure to antipsychotic drugs and risk of stroke. BMJ. 2008;336(7655):1222-1223. ↩︎
Engelsen BA, Fosse A. Platelet activation and antipsychotic drug use. Tidsskrift for den Norske Laegeforening. 2003;123(7):949-951. ↩︎
Rothschild AJ. Management of psychosis in the elderly. Focus. 2006;4(1):98-110. ↩︎
Abdulhamid MM, Li J, Wood C, et al. QTc prolongation in patients with schizophrenia. Journal of the National Medical Association. 2008;100(5):632-640. ↩︎
Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry. 1999;156(11):1686-1696. ↩︎
Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects. CNS Drugs. 2005;19(Suppl 1):1-93. ↩︎
Taylor D, McAskill R. Atypical antipsychotics and weight gain. Advances in Psychiatric Treatment. 2000;6(2):132-140. ↩︎
Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry. 2004;161(8):1334-1349. ↩︎
Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry. 2004;161(2 Suppl):1-56. ↩︎
Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. Journal of Clinical Psychiatry. 2003;64(Suppl 12):1-100. ↩︎
American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601. ↩︎
Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308(19):2020-2029. ↩︎
Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy. American Journal of Psychiatry. 2003;160(9):1740-1748. ↩︎
Cummings JL, Ballard C, Tariot P, et al. Pimavanserin for psychosis in Parkinson's disease-related dementia. American Journal of Geriatric Psychiatry. 2018;26(10):1080-1089. ↩︎
Lee D, Slomkowski M, Hefti N, et al. Brexpiprazole for the treatment of agitation associated with Alzheimer's disease. American Journal of Geriatric Psychiatry. 2023;31(6):453-465. ↩︎
Lonergan E, Britton AM, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database of Systematic Reviews. 2007;(2):CD003945. ↩︎